Article ID Journal Published Year Pages File Type
8736277 Allergology International 2018 5 Pages PDF
Abstract
Omalizumab has high efficacy in both the treatment and retreatment of CSU; however, relapse rates after discontinuation are high. Autoimmune markers may be helpful in predicting treatment response and relapse.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Immunology, Allergology and Rheumatology
Preview
Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients
Authors
, , ,